Related Experiment Video
Updated: Jan 4, 2026
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Thyroid cancer MR molecular imaging via SHP2-targeted nanoparticles
ZhongQian Hu1, JiaLe Qin2, TianKuan Li1
1Department of Ultrasound, Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu 210009, People's Republic of China.
Background:
Molecular imaging has generated a great demand to develop targeted contrast agents for MR imaging.
Materials And Methods:
In this study, we synthesized Src homology 2-containing phosphotyrosine phosphatase 2 (SHP2)-targeted and polylactic-co-glycolic acid--based nanoparticles (NPs), which encapsulated perfluoropentane and being chelated with gadolinium (Gd3+) as an efficient molecular probe for targeting MR imaging on thyroid carcinoma.
Results:
These NPs displayed practical properties and favorable biocompatibility in vitro. Furthermore, they showed abilities to specifically target thyroid cancer and enhance MRI as a contrast agent in both in vitro and in vivo experiments.
Conclusion:
This novel MR molecular imaging based on this SHP2-targeted contrast agent provides a useful and non-invasive method for the early detection of thyroid carcinoma.
